Every material Form 8-K ARTELO BIOSCIENCES, INC. has filed with the SEC since May 27, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
The SEC approved a Nasdaq rule requiring listed companies to maintain at least $5,000,000 in market value of listed securities, and Artelo was among about 180 Nasdaq companies initially flagged as below that threshold. The rule is now under a temporary stay, and the company does not know how long the stay will last or whether the rule will be reinstated in its current form.
SEC approved Nasdaq's $5M MVLS rule on July 22, 2026; a temporary stay was announced July 29, 2026.
On October 5, 2026, the SEC published Nasdaq's proposed change tying the rule's operative date to the end of the stay; comments are due October 29, 2026.
Artelo says it may consider raising capital through its at-the-market equity program or other financings if the rule applies to it, but has not committed to any course of action.
Artelo Biosciences filed a Certificate of Change in Nevada on August 26, 2026, to carry out a 1-for-9 reverse stock split of its common stock. The split takes effect at 5:00 p.m. Eastern Time on August 28, 2026, and the company said it is intended to improve the stock's marketability and liquidity. Each holder's pro-rata ownership is stated to remain unchanged, though the share count falls and the new CUSIP changes.
Each nine pre-split shares combine into one new share; outstanding shares fall from 4,929,966 to approximately 547,774.
Authorized common shares are reduced from 500,000,000 to 55,555,556.
Shares are expected to begin trading on a split-adjusted basis on Nasdaq on August 31, 2026, under new CUSIP 04301G805.
No fractional shares will be issued; holders entitled to a fraction receive one whole share.
Artelo Biosciences entered a sales agreement with H.C. Wainwright & Co. allowing it to sell up to $6,530,000 of common stock through an at-the-market program, paying the agent a 3.0% commission on gross sales. Separately, Craft Capital Management filed a FINRA arbitration claim against the company over a right of first refusal tied to a March 2026 private placement. The stock sales could dilute existing shareholders, and the outcome of the arbitration is not addressed in the filing.
Sales agreement dated May 26, 2026 allows sales of up to $6,530,000 of common stock, par value $0.001 per share
Sales agent receives a 3.0% commission on gross sales price; company has no obligation to sell any shares
Craft Capital seeks an $880,000 success fee, warrants valued at $880,000, monthly late fees and attorneys' fees over the March 30, 2026 private placement, which raised gross proceeds of about $11 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ARTELO BIOSCIENCES, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →